WuXi Biologics (Cayman) Inc. Stock price

Equities

2269

KYG970081173

Pharmaceuticals

Delayed Hong Kong S.E. 10:59:59 2024-02-25 pm EST 5-day change 1st Jan Change
18.9 HKD +3.62% Intraday chart for WuXi Biologics (Cayman) Inc. +13.86% -36.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 16.85B 2.34B 18.31B Sales 2024 * 20.29B 2.82B 22.06B Capitalization 70.05B 9.73B 76.15B
Net income 2023 * 4.01B 557M 4.35B Net income 2024 * 5B 694M 5.43B EV / Sales 2023 * 3.92 x
Net cash position 2023 * 3.94B 547M 4.28B Net cash position 2024 * 4.71B 654M 5.12B EV / Sales 2024 * 3.22 x
P/E ratio 2023 *
17.8 x
P/E ratio 2024 *
14.2 x
Employees 12,397
Yield 2023 *
-
Yield 2024 *
-
Free-Float 85.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.62%
1 week+13.86%
Current month-7.80%
1 month-23.01%
3 months-58.96%
6 months-58.23%
Current year-36.15%
More quotes
1 week
16.34
Extreme 16.34
19.28
1 month
14.70
Extreme 14.7
25.70
Current year
14.70
Extreme 14.7
33.40
1 year
14.70
Extreme 14.7
59.95
3 years
14.70
Extreme 14.7
148.00
5 years
14.70
Extreme 14.7
148.00
10 years
8.33
Extreme 8.3333
148.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 11-05-31
Director of Finance/CFO 56 21-08-22
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 23-05-05
Director/Board Member 77 17-04-30
Chairman 58 10-04-30
More insiders
Date Price Change Volume
24-02-25 18.9 +3.62% 20 484 558
24-02-23 18.24 -0.98% 24,285,990
24-02-22 18.42 +1.77% 33,635,660
24-02-21 18.1 +5.11% 55,332,760
24-02-20 17.22 +3.73% 33,041,600

Delayed Quote Hong Kong S.E., February 25, 2024 at 10:59 pm EST

More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
16.78 CNY
Average target price
47.33 CNY
Spread / Average Target
+182.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock WuXi Biologics (Cayman) Inc. - Hong Kong S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW